المؤلفون: Eva Andermann, Steven J. Frucht, Adriana Magaudda, Reetta Kälviäinen, Danielle Gerard, Philipp von Rosenstiel, Frederick Andermann, Pierre Genton, Christine de la Loge, Anne-Françoise Schlit

المصدر: Epilepsia. 57(2)

مصطلحات موضوعية: 0301 basic medicine, Adult, Male, medicine.medical_specialty, Levetiracetam, Adolescent, Progressive myoclonus epilepsy, Fructose, Brivaracetam, Placebo, Clonazepam, Double blind, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Double-Blind Method, Unverricht-Lundborg Syndrome, Topiramate, Internal medicine, Progressive myoclonic epilepsy, Antiepileptic drugs, Unified Myoclonus Rating Scale, Efficacy, Tolerability, Medicine, Humans, Adverse effect, Dose-Response Relationship, Drug, business.industry, Valproic Acid, Isoxazoles, Middle Aged, medicine.disease, Piracetam, Pyrrolidinones, Unverricht–Lundborg disease, 030104 developmental biology, Treatment Outcome, Neurology, Tolerability, Zonisamide, Anesthesia, Phenobarbital, Anticonvulsants, Drug Therapy, Combination, Female, Neurology (clinical), medicine.symptom, business, Myoclonus, 030217 neurology & neurosurgery, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::889e29e3280271136a5ad480ef6d8f27
https://pubmed.ncbi.nlm.nih.gov/26666500